About PRI

MISSION STATEMENT

  • Panorama identifies, initiates and incubates novel, proprietary bio-medical projects.

  • Projects originate from in-house research or by collaboration or license from outside of PRI.

  • As projects mature, they may be out-licensed to other companies or provide the basis for a PRI start-up company.

INSTITUTE PROFILE

  • Founded in 1991

  • Biotech/pharmaceutical incubator

  • Lab: heart of Silicon Valley, California

  • Spun out two dozen companies, many exits & 7 IPOs

  • 45,000 sq. ft. lab, offices in Sunnyvale

  • 15 scientists; drug development specialists

  • Major life science disciplines:

    • Medicinal chemistry

    • Pharmacology

    • Molecular biology & protein engineering

    • Cell Biology

 The Institute has a staff of 15 medical scientists (10 with MD and/or PhD degrees) with expertise in medicinal and organic chemistry, pharmacology, molecular and cell biology, plant molecular biology, oncology, immunology, infectious diseases and medicine. PRI has discovered and served as an incubator for a number of technologies and pharmaceutical projects that subsequently were licensed to development partners or incorporated into PRI portfolio companies.

The Institute receives revenues of >$2.0M annually from royalties, reagent sales and various contracts and grants from the USA National Institutes of Health, the Department of Energy, and the National Science Foundation.